(0.00%) 5 478.25 points
(-0.02%) 38 812 points
(0.03%) 19 928 points
(0.27%) $80.55
(1.11%) $2.82
(0.08%) $2 330.90
(-0.46%) $29.26
(-0.10%) $969.90
(0.03%) $0.932
(-0.11%) $10.64
(0.09%) $0.788
(-1.86%) $86.80
Live Chart Being Loaded With Signals
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC)...
Stats | |
---|---|
Šios dienos apimtis | 192 152 |
Vidutinė apimtis | 526 993 |
Rinkos kapitalizacija | 272.45M |
EPS | $-0.250 ( Q1 | 2024-05-14 ) |
Kita pelno data | ( $-0.430 ) 2024-08-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-2.40 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00700 (0.25%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Rizvi Syed Ali-aamir | Buy | 250 000 | Employee Stock Option (Right to Buy) |
2024-04-01 | Rizvi Syed Ali-aamir | Buy | 185 000 | Common Stock |
2024-04-01 | Rizvi Syed Ali-aamir | Buy | 0 | |
2024-03-01 | Mylet Johanna | Buy | 80 743 | Common Stock |
2024-03-01 | Mylet Johanna | Sell | 18 091 | Common Stock |
INSIDER POWER |
---|
88.60 |
Last 92 transactions |
Buy: 9 056 534 | Sell: 550 582 |
Tūris Koreliacija
Poseida Therapeutics, Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
PDSB | 0.806 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Poseida Therapeutics, Koreliacija - Valiuta/Žaliavos
Poseida Therapeutics, Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $64.70M |
Bruto pelnas: | $59.09M (91.32 %) |
EPS: | $-1.370 |
FY | 2023 |
Pajamos: | $64.70M |
Bruto pelnas: | $59.09M (91.32 %) |
EPS: | $-1.370 |
FY | 2022 |
Pajamos: | $130.36M |
Bruto pelnas: | $125.19M (96.03 %) |
EPS: | $-0.890 |
FY | 2021 |
Pajamos: | $31 238.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-0.00201 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Poseida Therapeutics,
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.